Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 23, 2025
Inside ExtendMax’s Compliance Journey After Global Recognition
EIN Presswire
·
May 23, 2025
Winning the People’s Choice Stevie Award marks more than a milestone — it reflects a decade of trust-building and customer-centric compliance services. HANOI, HANOI, VIETNAM, May 23, 2025 /EINPresswire.com/ -- After becoming the first Vietnamese company …
Pepe Heimer Introduces AI-powered Yield Optimization and Launches PEHEM Token Presale
GlobeNewswire
·
May 23, 2025
New York, NY, May 23, 2025 (GLOBE NEWSWIRE) -- Pepe Heimer, a new memecoin merging the prevalent meme culture with real utility, officially launched with a new approach to integrate AI-powered DeFi tools for yield optimization. The project seeks to solve …
Bitcoin breaks through $112,000 to hit a record high, and crypto enthusiasts earn passive income through APT mining machines
GlobeNewswire
·
May 23, 2025
New York, USA, May 23, 2025 (GLOBE NEWSWIRE) -- With the rapidly changing situation and the influx of advanced technologies, miners face huge challenges, including acquiring technical knowledge, securing specialized and expensive equipment, and optimizing …
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
GlobeNewswire
·
May 23, 2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix …
Forte Minerals Announces Private Placement of up to C$2.4 Million
GlobeNewswire
·
May 23, 2025
“Not for distribution to United States newswire services or for dissemination in the United States.” VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- Forte Minerals Corp. (“Forte” or the “Company”) (CSE: CUAU) (OTCQB: FOMNF) (Frankfurt: 2OA), …
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 23, 2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will take place during the “Developmental …
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 23, 2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
·
May 23, 2025
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP …
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies …
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
May 23, 2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, …
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
GlobeNewswire
·
May 23, 2025
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice …
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
GlobeNewswire
·
May 23, 2025
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research …
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
GlobeNewswire
·
May 23, 2025
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an …
El servicio nacional Drones como un Servicio (DaaS) de ZenaTech crece con el cierre de su quinta adquisición, sumando capacidades de inspección de líneas eléctricas
GlobeNewswire
·
May 23, 2025
VANCOUVER, Columbia Británica, May 22, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), una empresa de tecnología especializada en drones con IA (Inteligencia Artificial), Dron como un Servicio (DaaS), soluciones …
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of …
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 23, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, …